-
RemeGen’s H1 2022 Revenue Soars 1,094% on Aidixi, Taiai Sales
•
China-based biotech RemeGen (HKG: 9995) reported RMB 349 million (USD 50.5 million) in revenue for H1 2022, a 1,094.8% year-on-year surge, driven by sales of its two marketed products: Aidixi (disitamab vedotin), a HER2-targeted ADC for cancer, and Taiai (telitacicept), a fusion protein for autoimmune diseases. Product Approvals and Trials…
-
Beijing Adjusts UEBMI Account Management, Boosting Outpatient Coverage
•
The Beijing Municipal Medical Insurance Bureau has adjusted the management of Urban Employee Basic Medical Insurance (UEBMI) accounts, effective September 1. Employee contributions to Basic Medical Insurance (BMI) will now be fully allocated to personal accounts, while employer contributions will go to unified accounts. Retirees will receive a fixed allocation…
-
Junshi Biosciences’ H1 2022 Financials Show Tuoyi Sales Growth Despite Revenue Drop
•
Shanghai-based Junshi Biosciences (HKG: 1877) reported a 55.26% year-on-year (YOY) revenue decline to RMB 946.05 million (USD 136.9 million) in H1 2022, with net losses of RMB 912.4 million (USD 132 million). R&D spending rose 12% YOY to RMB 1.06 billion (USD 153.6 million), while cash reserves stood at RMB…
-
Connect Biopharma Completes Phase I Trial of CBP-174 for Itch in Skin Diseases
•
Sino-US biotech Connect Biopharma Holdings Ltd (NASDAQ: CNTB), headquartered in San Diego, California, and Taicang, Suzhou, China, announced the completion of a Phase I study for CBP-174, its small-molecule H3 receptor antagonist. The drug is being developed to treat pruritus (itch) associated with allergic and inflammatory skin diseases, including atopic…
-
RoosterBio Taps MBL Beijing Biotech as Exclusive Distributor in China
•
US-based RoosterBio Inc. has appointed MBL Beijing Biotech, a subsidiary of JSR Life Sciences Company, as its exclusive distributor in China. MBL will handle sales and distribution of RoosterBio’s expansion media, exosome collection media, bioreactor media, and genetic engineering media to local clients. Product PortfolioRoosterBio’s engineered media are used in…
-
Boehringer, Eli Lilly’s Jardiance Wins NMPA Approval for Heart Failure with Preserved Ejection Fraction
•
Boehringer Ingelheim and Eli Lilly (NYSE: LLY) announced that China’s National Medical Products Administration (NMPA) has approved a new indication for Jardiance (empagliflozin), an SGLT2 inhibitor, to treat heart failure in adult patients with preserved ejection fraction (HFpEF). Previously approved in China for type 2 diabetes and heart failure with…
-
E-nitiate Biopharma Raises RMB 100M in Series A to Advance Autoimmune Disease Drugs
•
China-based E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd, a drug developer focused on autoimmune diseases, has raised RMB 100 million (USD 14.5 million) in a Series A financing round. The round was led by M Momentum Venture and included contributions from Tailong Capital, Hangzhou Linping State-owned Capital Investment, and Hangzhou Jintou Industry…
-
Kangtai Bio Partners with Philippine Firm on Pneumonia Vaccines
•
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has partnered with an unnamed Philippine enterprise to promote its 13-valent and 23-valent pneumonia vaccines in the Philippines. The collaboration aims to enhance regulatory filing, promotion, distribution, marketing, and sales, increasing accessibility and affordability in the Philippines and other emerging markets. Vaccine…
-
MicroPort Scientific Posts 10% Revenue Growth Despite COVID-19 in 2022 Interim Results
•
China-based MicroPort Scientific Corp. (HKG: 0853) reported unaudited 2022 interim results ending June 30, 2022, with revenues of USD 405 million, up 10.1% year-on-year (YOY) excluding exchange rate impacts. The growth was driven by strong performance in key business segments despite COVID-19-related challenges. Business Segment Highlights Financial PerformanceThe company reported…
-
Merck’s Gardasil 9-Valent HPV Vaccine Approved for Expanded Age Range in China
•
US-based Merck Sharp & Dohme (MSD; NYSE: MRK) announced that China’s National Medical Products Administration (NMPA) has approved an expanded indication for its Gardasil 9-valent human papillomavirus (HPV) vaccine. The vaccine, initially approved for females aged 16–26, can now be administered to females aged 9–45. Vaccine Details Epidemiological Context Vaccination…
-
Onekdrug Raises Series B+ Funding to Boost Pharmaceutical B2B Services
•
Hunan Wholesale Pharmaceutical Technology Co., Ltd, operating as Onekdrug, has raised tens of millions of US dollars in a Series B+ financing round led by C-Bridge Capital, with contributions from existing investors Cenova Capital and Unicorn Capital Partners. The proceeds will enhance the company’s service capabilities, including operations, technology, and…
-
Sinocelltech’s Ripertamab Wins NMPA Approval for DLBCL Treatment
•
China-based Sinocelltech Group Ltd (SHA: 688520) has received New Drug Application (NDA) approval from the National Medical Products Administration (NMPA) for its biosimilar ripertamab (SCT400), a CD20 monoclonal antibody (mAb) targeting newly diagnosed CD20-positive diffuse large B-cell non-Hodgkin lymphoma (DLBCL). Drug ProfileRipertamab is a biosimilar of Roche’s Mabthera (rituximab) and…
-
Fosun Pharma’s H1 2022 Revenue Rises 25.9% on New Drug Launches, Global Expansion
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) reported RMB 21.34 billion (USD 3 billion) in H1 2022 revenue, up 25.88% year-on-year (YOY), and RMB 1.86 billion (USD 268.8 million) in net profits, up 18.57% YOY. Income from ex-China markets reached RMB 7.59 billion (USD 1 billion), accounting for 35.58%…
-
Clover Biopharma’s SCB-2019 Vaccine Shows Strong Immune Response to Omicron BA.5
•
China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) announced positive Phase II/III trial results for its COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), demonstrating a robust immune response against the Omicron BA.5 subvariant, the dominant strain globally. Trial DesignThe global, double-blind, randomized, controlled SPECTRA trial included two cohorts: Immune Response
-
Staidson and J&J’s Teclistamab Gain Breakthrough Designation for Hemophilia and Myeloma
•
The Center for Drug Evaluation (CDE) has indicated that Staidson (Beijing) Pharmaceutical Co., Ltd’s (SHE: 300204) STSP-0601 and Johnson & Johnson’s teclistamab are set to receive breakthrough therapy designations (BTDs). STSP-0601 is indicated for on-demand treatment of bleeding in hemophilia A or B patients with inhibitors, while teclistamab targets relapsed…
-
Fosun Pharma to Invest RMB 1B in Chengdu Vaccine Base
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) announced that its subsidiaries, Shanghai Fosun Pharmaceutical Development Co., Ltd and Fosun Adgenvax, will invest RMB 1 billion (USD 144.6 million) to establish an innovative vaccine headquarters and industrialization base in Chengdu Tianfu International Bio-town. The project is expected to be completed…
-
InnoCare Pharma and CStone Pharmaceuticals’ Drugs Receive Prioritized CDE Review
•
The Center for Drug Evaluation (CDE) has granted prioritized review status to InnoCare Pharma’s (HKG: 9969) orelabrutinib (a Bruton’s tyrosine kinase, BTK inhibitor) and CStone Pharmaceuticals’ (HKG: 2616) sugemalimab (a PD-L1 inhibitor, Cejemly). Orelabrutinib is filed for marginal zone lymphoma (MZL), while sugemalimab seeks approval for relapsed/refractory extranodal NK/T-cell lymphoma…
-
Luca Healthcare Raises Pre-Series A Funding for Digital Biomarker R&D
•
Shanghai-based Luca Healthcare Co., Ltd, a firm specializing in digital biomarkers and therapeutics, has raised tens of millions of renminbi in a pre-Series A financing round led by Lightspeed China, with participation from JinDing Capital and Picus Capital. The funds will support R&D, validation of digital target pipelines, international collaborations,…
-
Biocytogen and Tracon Pharmaceuticals Gain FDA IND Approval for Sarcoma Trial
•
China-based Biocytogen (Beijing) Co., Ltd and US-based Tracon Pharmaceuticals Inc. (Nasdaq: TCON) announced that the US FDA has approved an IND application to conduct a clinical trial of YH001 in combination with envafolimab or doxorubicin for sarcoma patients, including those who have not been previously treated. Trial DesignThe Phase I/II…
-
Hengrui Medicine’s Dalpiciclib Hits Superiority Criteria in Phase III Study
•
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that its Phase III SHR6390-III-302 study for dalpiciclib, a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor, has met pre-set superiority criteria. The drug, combined with letrozole or anastrozole, significantly prolonged progression-free survival (PFS) in patients with HR-positive, HER2-negative advanced breast…
